AGENUS INC Net Fee Amt
AGENUS INC (AGEN) had Net Fee Amt of $238.62 as of 2026-09-10, per its S-3 filed 2026-09-11.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-11
- 2026-09-10: Net Fee Amt $238.62.
- 2026-09-02: Net Fee Amt $270.68.
- 2026-08-07: Net Fee Amt $83.94K.
- 2026-07-17: Net Fee Amt $1.47K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-10 | $238.62 S-3 · filed 2026-09-11 |
| 2026-09-02 | $270.68 S-8 · filed 2026-09-02 |
| 2026-08-07 | $83.94K S-3 · filed 2026-08-07 |
| 2026-07-17 | $1.47K S-3 · filed 2026-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |